Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2020

Year

Stéfano Kim, Bruno Buecher, Thierry André, Marine Jary, François‐Clément Bidard, François Ghiringhelli, Éric François, Denis Smith, Christelle de la Fouchardière, Jérôme Desrame,

BMC Cancer